A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Clinical trial NCT06298552 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06298552
Sponsor: argenx
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Generalized Myasthenia Gravis gMG Myasthenia Gravis, Generalized Myasthenia Gravis

Start date: 2024-04-16
Primary completion: 2025-06-30
Enrollment: 119

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.